106 related articles for article (PubMed ID: 3132198)
1. Plasma 5-S-cysteinyldopa as an index of melanogenesis.
Nimmo JE; Gawkrodger DJ; O'Docherty CS; Going SM; Percy-Robb IW; Hunter JA
Br J Dermatol; 1988 Apr; 118(4):487-95. PubMed ID: 3132198
[TBL] [Abstract][Full Text] [Related]
2. 5-S-Cysteinyldopa and dopa in serum during treatment with 8-methoxypsoralen and UVA light.
Hansson C; Rorsman H; Rosengren E; Tegner E
Acta Derm Venereol; 1981; 61(3):251-5. PubMed ID: 6167110
[TBL] [Abstract][Full Text] [Related]
3. Observations on PUVA treatment of psoriasis and on 5-S-cysteinyldopa after exposure to UV light.
Tegner E
Acta Derm Venereol Suppl (Stockh); 1983; 107():1-68. PubMed ID: 6410637
[No Abstract] [Full Text] [Related]
4. Serum 5-S-cysteinyldopa levels in patients with psoriasis undergoing narrowband ultraviolet B phototherapy.
Kikuchi K; Wakamatsu K; Tada Y; Komine M; Ito S; Tamaki K
Clin Exp Dermatol; 2008 Nov; 33(6):750-3. PubMed ID: 18954414
[TBL] [Abstract][Full Text] [Related]
5. 5-S-cysteinyldopa excretion after treatment with 8-methoxypsoralen and UVA light.
Agrup G; Hansson C; Rorsman H; Rosengren A-M ; Rosengren E; Tegner E
J Invest Dermatol; 1978 Jan; 70(1):25-6. PubMed ID: 618976
[TBL] [Abstract][Full Text] [Related]
6. 5 years' experience of 5-S-cysteinyldopa in melanoma diagnosis.
Agrup G; Agrup P; Andersson T; Hafström L; Hansson C; Jacobsson S; Jönsson PE; Rorsman H; Rosengren AM; Rosengren E
Acta Derm Venereol; 1979; 59(5):381-8. PubMed ID: 93360
[TBL] [Abstract][Full Text] [Related]
7. Plasma 5-S-cysteinyldopa correlates with tumor size in melanoma-bearing mice.
Hu F; Woodward WR; Peterson LL
J Invest Dermatol; 1988 Feb; 90(2):149-51. PubMed ID: 3123557
[TBL] [Abstract][Full Text] [Related]
8. 5-S-cysteinyldopa and pigment response to UVA light.
Tegner E; Rorsman H; Rosengren E
Acta Derm Venereol; 1983; 63(1):21-5. PubMed ID: 6191484
[TBL] [Abstract][Full Text] [Related]
9. Urinary excretion of 6-hydroxy-5-methoxyindole-2-carboxylic acid and 5-S-cysteinyldopa during PUVA treatment.
Hansson C; Wirestrand LE; Aronsson A; Rorsman H; Rosengren E
Photodermatol; 1985 Apr; 2(2):52-7. PubMed ID: 3929237
[TBL] [Abstract][Full Text] [Related]
10. Plasma 5-S-cysteinyldopa differentiates patients with primary and metastatic melanoma from patients with dysplastic nevus syndrome and normal subjects.
Peterson LL; Woodward WR; Fletcher WS; Palmquist M; Tucker MA; Ilias A
J Am Acad Dermatol; 1988 Sep; 19(3):509-15. PubMed ID: 3139723
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of melanin-related metabolites as markers of solar ultraviolet-B radiation.
Wakamatsu K; Ito S
Pigment Cell Res; 2006 Oct; 19(5):460-4. PubMed ID: 16965276
[TBL] [Abstract][Full Text] [Related]
12. The effect of UVB light on serum concentrations of 5-S-cysteinyldopa.
Tegner E; Agrup G; Rosengren E
Acta Derm Venereol; 1983; 63(2):149-52. PubMed ID: 6189331
[No Abstract] [Full Text] [Related]
13. Characterization of melanogenesis in mouse and guinea pig hair by chemical analysis of melanins and of free and bound dopa and 5-S-cysteinyldopa.
Ito S; Fujita K; Takahashi H; Jimbow K
J Invest Dermatol; 1984 Jul; 83(1):12-4. PubMed ID: 6429251
[TBL] [Abstract][Full Text] [Related]
14. Urinary excretion of 5-S-cysteinyldopa is enhanced by PUVA and is independent of skin type.
Tardy J; Barrois JP; Bendelac A; Leonard F; Triller R; Jardillier JC; Kalis B
Photodermatol; 1987 Aug; 4(4):205-8. PubMed ID: 3124084
[TBL] [Abstract][Full Text] [Related]
15. Increased cysteinyldopa plasma levels hint to melanocyte as stress sensor in psoriasis.
Panzella L; Wakamatsu K; Monfrecola G; Ito S; Ayala F; Napolitano A
Exp Dermatol; 2011 Mar; 20(3):288-90. PubMed ID: 21323749
[TBL] [Abstract][Full Text] [Related]
16. Plasma 5-S-cysteinyldopa concentrations in oculocutaneous albinism.
Nimmo JE; Hunter JA; Percy-Robb IW; Jay B; Phillips CI; Taylor WO
Acta Derm Venereol; 1985; 65(2):169-71. PubMed ID: 2408424
[TBL] [Abstract][Full Text] [Related]
17. Comparison of phaeomelanin and its precursor 5-S-cysteinyldopa in the serum of melanoma patients.
Wakamatsu K; Yokochi M; Naito A; Kageshita T; Ito S
Melanoma Res; 2003 Aug; 13(4):357-63. PubMed ID: 12883361
[TBL] [Abstract][Full Text] [Related]
18. Urinary excretion of 5-S-cysteinyldopa in relation to skin type, UVB-induced erythema, and melanocyte proliferation in human skin.
Stierner U; Rosdahl I; Augustsson A; Kågedal B
J Invest Dermatol; 1988 Nov; 91(5):506-10. PubMed ID: 3139773
[TBL] [Abstract][Full Text] [Related]
19. The quantitative determination of 5-S-cysteinyldopa and dopa in normal serum and in serum from patients with malignant melanoma by means of high-pressure liquid chromatography.
Hansson C; Edholm LE; Agrup G; Rorsman H; Rosengren AM; Rosengren E
Clin Chim Acta; 1978 Sep; 88(3):419-27. PubMed ID: 699334
[TBL] [Abstract][Full Text] [Related]
20. The urinary melanogen cysteinyldopa in melanoma and in suntanning: Australian experience.
Nixon PF
Aust N Z J Surg; 1978 Feb; 48(1):17-21. PubMed ID: 276342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
